Slc6a6, also known as TauT, is a transmembrane transporter belonging to the solute carrier family 6. It is crucial for maintaining taurine homeostasis as it facilitates the transport of taurine, an amino-acid-like compound involved in various physiological processes such as osmoregulation, antioxidation, and neurotransmission [2,3]. Genetic models, like gene knockout mouse models, are valuable for studying Slc6a6's functions in vivo.

In cancer research, Slc6a6 has been found to be correlated with aggressiveness and poor outcomes in multiple cancers. In gastric cancer, its high expression is associated with poor prognosis, and hypomethylation contributes to its upregulation [1]. In colorectal cancer, SLC6A6 knockdown attenuated cell survival and enhanced drug sensitivity, indicating its role in promoting cell survival and multidrug resistance [5].

In the context of heart failure, Pdk1 deficiency-induced heart failure is related to disturbances in taurine homeostasis triggered by Slc6a6 [2]. Also, in vascular smooth muscle cells, SLC6A6 overexpression suppresses neointimal formation by inhibiting cell proliferation and migration via the Wnt/β-catenin signaling pathway [4].

In conclusion, Slc6a6 is essential for taurine transport and homeostasis, playing important roles in multiple biological processes and disease conditions. Studies using gene knockout or knockdown models have revealed its significance in cancer, heart failure, and vascular remodeling. These findings contribute to our understanding of disease mechanisms and may provide potential therapeutic targets for related diseases.